Last reviewed · How we verify
Hypromellose Eye Drop
Hypromellose Eye Drop is a Artificial tear lubricant / Ophthalmic demulcent Small molecule drug developed by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.. It is currently FDA-approved for Dry eye syndrome / Keratoconjunctivitis sicca, Ocular surface protection and lubrication. Also known as: zhenshishuang.
Hypromellose is a cellulose-based polymer that acts as an artificial tear lubricant, coating and protecting the ocular surface.
Hypromellose eye drops are used to treat various eye conditions, including Dry Eye Syndromes, Computer Vision Syndrome, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, and Ocular Surface Disease. The exact mechanism of action of hypromellose eye drops is unknown, but they are known by various synonyms such as ARTELAC, ARTELAC SDU, BROLENE, DACRIOSOL, GONISOL, and HIPROMELOSA.
At a glance
| Generic name | Hypromellose Eye Drop |
|---|---|
| Also known as | zhenshishuang |
| Sponsor | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
| Drug class | Artificial tear lubricant / Ophthalmic demulcent |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Hypromellose (hydroxypropyl methylcellulose) is a viscous ophthalmic lubricant that mimics natural tear film by forming a protective hydrophilic layer over the cornea and conjunctiva. It reduces friction, prevents evaporation of tears, and provides sustained moisture to relieve dry eye symptoms. The polymer's viscoelastic properties allow prolonged contact time with the ocular surface.
Approved indications
- Dry eye syndrome / Keratoconjunctivitis sicca
- Ocular surface protection and lubrication
Common side effects
- Blurred vision
- Eye irritation
- Mild ocular discomfort
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hypromellose Eye Drop CI brief — competitive landscape report
- Hypromellose Eye Drop updates RSS · CI watch RSS
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. portfolio CI
Frequently asked questions about Hypromellose Eye Drop
What is Hypromellose Eye Drop?
How does Hypromellose Eye Drop work?
What is Hypromellose Eye Drop used for?
Who makes Hypromellose Eye Drop?
Is Hypromellose Eye Drop also known as anything else?
What drug class is Hypromellose Eye Drop in?
What development phase is Hypromellose Eye Drop in?
What are the side effects of Hypromellose Eye Drop?
Related
- Drug class: All Artificial tear lubricant / Ophthalmic demulcent drugs
- Manufacturer: Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye syndrome / Keratoconjunctivitis sicca
- Indication: Drugs for Ocular surface protection and lubrication
- Also known as: zhenshishuang
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing